Drugs / BIBR 796 BS
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT02211144 | Mar → Nov 2002 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02209831 | Nov 2001 → Jan 2002 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02211157 | Mar → Jul 2000 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02208856 | Sep → Dec 1999 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02209792 | Oct 2001 → Jan 2004 | Crohn disease | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 2 | NCT02209779 | May 2001 → Jun 2002 | rheumatoid arthritis | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BIBR 796 BS | “Device: BIBR 796 BS” NCT02209831 ↗ |
| Known as | BIRB 796 BS | “Dose Finding Study of BIRB 796 BS (10, 20, 30, and 60 mg*)” NCT02209792 ↗ |
| Route | Oral | “Administered Twice a Day Orally Over 4 Weeks” NCT02209779 ↗ |